39.02 0.00 (0.00%)
After hours: 4:53PM EDT
|Bid||39.13 x 2200|
|Ask||39.14 x 1300|
|Day's Range||38.90 - 39.32|
|52 Week Range||34.38 - 43.30|
|Beta (3Y Monthly)||0.47|
|PE Ratio (TTM)||41.07|
|Forward Dividend & Yield||1.40 (3.72%)|
|1y Target Est||N/A|
AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite heart attack survivors nationwide and elevate the importance of daily heart health management. The tour will kick off with a stop in Tampa, Florida, on June 5th, connecting local survivors with Bob Harper to share stories of strength and resilience. Further, the Survivors Have Heart initiative will bring together cardiovascular patient advocacy organizations, healthcare providers, policymakers and other community leaders to celebrate survivorship and champion the importance of cardiovascular health as part of a long-term healthy lifestyle.
A new integrated analysis of Phase III data for FASENRA® (benralizumab) shows that patients with severe eosinophilic asthma who were continuously treated with the medicine for up to two years reduced their use of oral corticosteroids (OCS) and experienced a sustained improvement in exacerbation rates, lung function, asthma control and health-related quality of life. The analysis, presented today at the American Thoracic Society (ATS) 2019 International Conference, provides long-term efficacy and safety data for FASENRA from the one-year Phase III SIROCCO and CALIMA exacerbation trials, the one-year Phase III BORA extension trial and the 28-week Phase III ZONDA OCS-sparing trial.
Data focused on breaking treatment boundaries, treating patients earlier in their disease, and raising the bar for better outcomes
AstraZeneca is teaming up with PGA golf champion Jason Day to encourage newly diagnosed Stage IV non-small cell lung cancer patients to ask their doctor about biomarker testing (sometimes referred to as molecular testing or mutation testing), which can help patients and their physician find the treatment options that are right for them. AstraZeneca is partnering with the world-renowned golf pro to launch the Test It Back campaign, focused on ensuring complete biomarker testing becomes standard of care at every late-stage lung cancer diagnosis. The Test It Back site includes a series of inspiring videos featuring Day and his mother, Dening, whose decision to get mutation testing of her Stage IV non-small cell lung cancer last year informed her treatment decisions.
The oncology community gathered together last night to celebrate the winners of the first Cancer Community (C2) Awards. The awards – a partnership between AstraZeneca and Scientific American Custom Media – includes nominations submitted by organizations from across the cancer ecosystem and participation from an esteemed panel of third-party judges. “There is so much progress happening in cancer care, but it takes a village to make real change,” expressed Olivier Nataf, Head of US Oncology, AstraZeneca.
AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the investigational MEK 1/2 inhibitor and potential new medicine selumetinib.
FARXIGA reduced major adverse cardiovascular events by 16% in patients who had a prior heart attack
First sub-analyses from Phase III DECLARE-TIMI 58 trial selected for late-breaking clinical trial and oral presentations
NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
PRESS RELEASE: REGULATED INFORMATION Thursday, 28 February 2019, 07:00 CET BIOCARTIS ANNOUNCES 2018 RESULTS AND 2019 OUTLOOK Mechelen, Belgium , 28 February 2019 - Biocartis Group NV (the `Company` ...
Updated label confirms the well-established efficacy and safety profile for FARXIGA and XIGDUO XR
Phase III POLO Trial Met Primary Endpoint of Progression-Free Survival
BRILINTA reduced cardiovascular events in these patients with no prior heart attack or stroke
SAN DIEGO , Feb. 14, 2019 /PRNewswire/ -- Tanabe Research Laboratories U.S.A. Inc. (TRL), a subsidiary of Mitsubishi Tanabe Pharmaceutical Corporation, is a California based research, development and clinical ...
PRESS RELEASE Lund Sweden, February 11 2019 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announces that their partner NeoTX enters a clinical collaboration with AstraZeneca Group Plc (NYSE: AZN) global biologics ...
Teva Pharmaceutical Industries’ stock jumped 3.79% Wednesday, to close the day at $19.46. The stock recorded a trading volume of 10,428,002 shares, which was below its three months average volume of 11,332,324 shares. In the last year, Teva Pharmaceutical Industries’ shares have traded in a range of 14.59 - 25.96.
TSE: 4565), announces it has been notified today by its strategic alliance partner AstraZeneca (AZN.L) that it has reached a clinical development milestone with its partnered next generation immuno-oncology candidate AZD4635, triggering a US$15 million payment from AstraZeneca. AZD4635 is a potent and selective, orally available, small molecule adenosine 2A receptor antagonist discovered by the Company and exclusively licensed to AstraZeneca globally in 2015.
AstraZeneca today announced that the Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoint for the treatment of patients with anemia in chronic kidney disease (CKD) that are either non-dialysis-dependent (NDD) or dialysis-dependent (DD), respectively. Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and a potential first-in-class new medicine to treat anemia in CKD being jointly developed and commercialized by AstraZeneca and FibroGen, Inc.
WILMINGTON, Del.-- -- AstraZeneca and Merck’s LYNPARZA reduced the risk of disease progression or death by 70% compared to placebo following response to platinum-based chemotherapy First PARP inhibitor approved in 1st-line maintenance for BRCA m advanced ovarian cancer AstraZeneca and Merck & Co., Inc., today announced that the US Food and Drug Administration has approved LYNPARZA for use as maintenance ...
- Pyramid Biosciences to exclusively develop AstraZeneca's novel cell surface receptor (TRK) program - Targeting range of dermatological and inflammatory diseases, including psoriasis and atopic dermatitis ...
FDA grants breakthrough device designation to GuardantOMNI test usedfor plasma-based tumor mutational burden analysis in AstraZeneca trial Agreement covers immunotherapy and.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
26 months median duration of response achieved in relapsed or refractory mantle cell lymphoma at updated two-year analysis
PRESS RELEASE : 29 November 2018, 07:00 CET Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results Mechelen, Belgium, 29 November 2018 - Biocartis Group NV (the ...
27 scientific presentations, including long-term data from CALQUENCE in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukemia